EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Consistency of drug-resistant mutations in plasma and peripheral blood mononuclear cells of patients with treatment-naïve and treatment-experienced HIV-1 infection

Jie Ma, Zhaoyun Chen, Chaohong Fu, Shuguang Wei, Jinjin Liu, Xuan Yang, Xuhui Chen, Qingxia Zhao, Yan Sun, Yuqi Huo

Frontiers in Cellular and Infection Microbiology · 2023

DOI: 10.3389/fcimb.2023.1249837 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Jie Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Medicine, The Sixth People's Hospital of Zhengzhou, Zhengzhou, China. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Genotypic drug resistance testing is cursrently recommended by the World Health Organization for all patients infected with human immunodeficiency virus type 1 (HIV-1) undergoing care or switching regimes due to failure with previous antiretroviral therapy (ART). Patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) who meet the criteria for free testing for genotypic drug resistance due to poor adherence in Henan Province may resume their previous regimens before resampling. Therefore, resistance testing based on plasma RNA can fail in a proportion of patients. Resistance testing based on peripheral blood mononuclear cells (PBMCs) is an alternative option. In this study, we investigated the differences in drug-resistant mutations (DRMs) between plasma HIV RNA and proviral DNA in treatment-experienced and treatment-naïve patients.

Methods

Matched plasma RNA and proviral DNA samples of 66 HIV-1 infected treatment-naïve and 78 treatment-experienced patients were selected for DRM analysis and comparison.

Results

DRMs were detected in 27.3% (18/66) of treatment-naïve and 80.8% (63/78) of treatment-experienced samples. Resistance to at least one drug was detected based on analysis of plasma RNA and proviral DNA in 7.6% (5/66) and 9.1% (6/66) of treatment-naïve patients and in 79.5% (62/78) and 78.2% (61/78) of treatment-experienced patients, respectively. Furthermore, 61/66 (92.4%) of treatment-naïve patients showed concordant RNA and DNA drug resistance. When drug resistance was defined as intermediate and high, the concordance of drug resistance profiles of paired RNA and proviral DNA samples derived from treatment-naïve patients were up to 97.0% compared with only 80.8% (63/78) in treatment-experienced patients.

Discussion

Our data indicate that drug resistance testing based on plasma RNA or proviral DNA might be interchangeable in treatment-naïve patients, whereas plasma RNA-based testing remains the best choice for drug resistance analysis in patients with ART failure in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsAcquired Immunodeficiency SyndromeHumansLeukocytes, MononuclearDrug Resistance, ViralRNA, ViralDNA, ViralProvirusesMutation

Stichwörter der Autor:innen

HIV RNAdrug-resistant mutationsgenotypic drug resistanceperipheral blood mononuclear cellsproviral DNA

Substanzen

RNA, ViralDNA, Viral

Autor:innen und Institutionen

  • Center for Translational Medicine, The Sixth People's Hospital of Zhengzhou, Zhengzhou, China.

Zitieren

APA

Ma, J., Chen, Z., Fu, C., Wei, S., Liu, J., Yang, X., Chen, X., Zhao, Q., Sun, Y., & Huo, Y. (2023). Consistency of drug-resistant mutations in plasma and peripheral blood mononuclear cells of patients with treatment-naïve and treatment-experienced HIV-1 infection. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1249837

Vancouver

Ma J, Chen Z, Fu C, Wei S, Liu J, Yang X, et al. Consistency of drug-resistant mutations in plasma and peripheral blood mononuclear cells of patients with treatment-naïve and treatment-experienced HIV-1 infection. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1249837

BibTeX
@article{Ma2023,
  author = {Ma, Jie and Chen, Zhaoyun and Fu, Chaohong and Wei, Shuguang and Liu, Jinjin and Yang, Xuan and Chen, Xuhui and Zhao, Qingxia and Sun, Yan and Huo, Yuqi},
  title = {Consistency of drug-resistant mutations in plasma and peripheral blood mononuclear cells of patients with treatment-naïve and treatment-experienced HIV-1 infection},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  doi = {10.3389/fcimb.2023.1249837}
}
Kostenlos starten →